Trial Profile
A Phase 1/2 randomized, controlled clinical trial of AB-PA01 in patients patients with P. aeruginosa bacteremia
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2018
Price :
$35
*
At a glance
- Drugs AP PA01 (Primary)
- Indications Pseudomonal infections
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2018 New trial record
- 18 Sep 2018 According to an AmpliPhi Biosciences Corporation media release, FDA is in general agreement with the design of proposed this clinical trial and no additional preclinical or clinical data are required to proceed with both trials.